AstraZeneca’s first-in-class pan-AKT inhibitor Truqap was unable to improve overall survival (OS) in a phase 3 trial in triple-negative breast cancer (TNBC), denting the prospects of the new drug.

Initial OnKure Therapeutics, Inc. data from PIKture-01 study on OKI-219 for PI3Ka-H1047R breast cancer expected in Q4, 2024.

AstraZeneca PLC (OTCMKTS:AZNCF – Get Free Report) was the target of a large decrease in short interest during the month of October. As of October 15th, there was short interest totalling 37,100 shares ...

Dakota Wealth Management cut its stake in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 1.8% in the 3rd quarter, ...

Schoenfeld, whose organization supported the study, told MNT why he was optimistic about the findings: “This research is especially hopeful following the recent failure of Truqap, a targeted ...

Key Takeaways Zacks earnings estimates for AstraZeneca are currently at $4.06 per share. However, the earnings picture ...

It made $229 million in sales in the first six months of this year, a decline of 6% on the previous year, likely because it is facing competition from AstraZeneca's AKT inhibitor Truqap ...

“[For] someone who has a PIK3CA mutation, you may be looking at medicines like capivasertib (Truqap) or alpelisib (Piqray). If someone has an ESR mutation, maybe looking at elacestrant (Orserdu).” ...

We continue to have strong expectations for several pipeline drugs, including camizestrant (breast cancer), Truqap (breast cancer), Wainua (rare disease), and Voydeya (rare disease). In looking at ...